Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Fernández-Martínez, Aranzazuca
• dc.contributor.author Albanell Mestres, Joanca
• dc.contributor.author Martin, Miquelca
• dc.date.accessioned 2018-07-09T08:10:29Z
• dc.date.available 2018-07-09T08:10:29Z
• dc.date.issued 2017
• dc.description.abstract PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.
• dc.format.mimetype application/pdf
• dc.identifier.citation Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M. et al. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget. 2017 Mar 28;8(13):21930-21937. DOI: 10.18632/oncotarget.15748
• dc.identifier.doi http://dx.doi.org/10.18632/oncotarget.15748
• dc.identifier.issn 1949-2553
• dc.identifier.uri http://hdl.handle.net/10230/35067
• dc.language.iso eng
• dc.publisher Impact Journalsca
• dc.relation.ispartof Oncotarget. 2017 Mar 28;8(13):21930-7
• dc.rights Copyright : © 2017 Fernández-Martinez et al. This article is distributed under the terms of the https://creativecommons.org/licenses/by/3.0/ (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/3.0/
• dc.subject.keyword Ki67
• dc.subject.keyword PAM50/Prosigna
• dc.subject.keyword Breast cancer
• dc.subject.keyword Estrogen receptor-positive/HER2-negative
• dc.subject.other Mama -- Càncer
• dc.subject.other Estrògens -- Receptors
• dc.title Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion